Limited P-glycoprotein mediated efflux for anti-epileptic drugs

Journal of Drug Targeting

Volumn 14, Issue 5, 2006, Pages 291-300

  Crowe, Andrew ^a   Teoh, Yee Khuan ^a  

^a CURTIN UNIVERSITY   (Australia)

Author keywords

Carbamazepine; Drug absorption; Epilepsy; P glycoprotein; Phenobarbitone; Phenytoin

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETHOSUXIMIDE; GABAPENTIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PROBENECID; SULFINPYRAZONE; TOPIRAMATE; VIGABATRIN; VINBLASTINE;

ARTICLE; CELL CLONE; CELL STRAIN CACO 2; CELL TRANSPORT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG TRANSPORT; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MONOLAYER CULTURE; PRIORITY JOURNAL; PROTEIN DETERMINATION; REAL TIME POLYMERASE CHAIN REACTION;

ANTICONVULSANTS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; P-GLYCOPROTEIN;

EID: 33746824653     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860600720814     Document Type: Article

References (49)

1. Alsenz, J and Steffen, H and Alex, R. (1998) Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers Pharm Res, 15, pp. 423-428.
2. Aronica, E and Gorter, JA and Jansen, GH and Van Veelen, CWM and Van Rijen, PC and Leenstra, S and Ramkema, M and Scheffer, GL and Scheper, RJ and Troost, D. (2003) Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: Focal cortical dysplasia and glioneuronal tumors Neuroscience, 118, pp. 417-429.
3. Artursson, P. (1990) Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorbtive (Caco-2) cells J Pharm Sci, 79, pp. 476-482.
4. Artursson, P and Palm, K and Luthman, K. (1996) Caco-2 monolayers in experimental and theoretical predictions of drug transport Adv Drug Del Rev, 22, pp. 67-84.
5. Belal, F and Abdine, H and Al-Majed, A and Khalil, NY. (2002) Spectrofluorimetric determination of vigabatrin and gabapentin in urine and dosage forms through derivatization with fluorescamine J Pharm Biomed Anal, 27, pp. 253-260.
6. Burton, P and Goodwin, J and Conradi, R and Ho, N and Hilgers, R. (1997) In vitro permeability of peptidomimetic drugs: The role of polarized efflux pathways as additional barriers to absorption Adv Drug Del Rev, 23, pp. 143-156.
7. Chen, S and Carvey, PM. (1999) Rapid approach to the quantitative determination of topiramate (2,3:4,5-bis-O-(1-methylethylidene)-beta d fructopyranose sulfamate) in human plasma by liquid-liquid extraction and flow-injection negative-ion electrospray mass spectrometry Rapid Commun Mass Spectrom, 13, pp. 1980-1984.
8. Crowe, A. (2002) The influence of P-glycoprotein on morphine transport in Caco-2 cells. Comparison with paclitaxel Eur J Pharmacol, 440, pp. 7-16.
9. Crowe, A and Lemaire, M. (1998) In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: Comparison with rapamycin Pharm Res, 15, pp. 1666-1672.
10. Deckers, CLP and Genton, P and Sills, GJ and Schmidt, D. (2003) Current limitations of antiepileptic drug therapy: A conference review Epilepsy Res, 53, pp. 1-17.
11. Didziapetris, R and Japertas, P and Avdeef, A and Petrauskas, A. (2003) Classification analysis of P-glycoprotein substrate specificity J Drug Target, 11, pp. 391-406.
12. Dimitrijevic, D and Whitton, PS and Domin, M and Welham, K and Florence, AT. (2001) Increased vigabatrin entry into the brain by polysorbate 80 and sodium caprate J Pharm Pharmacol, 53, pp. 149-154.
13. Horie, K and Tang, F and Borchardt, R. (2003) Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter Pharm Res, 20, pp. 161-168.
14. Hosoya, K and Kim, K and Lee, V. (1996) Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers Pharm Res, 13, pp. 885-890.
15. Ingels, F and Deferme, S and Destexhe, E and Oth, M and Van den Mooter, G and Augustijns, P. (2002) Simulated intestinal fluid as transport medium in the Caco-2 Cell culture model Int J Pharm, 232, pp. 183-192.
16. Kazuhiro, K and Lee, R and Xu, H and Harper, P and Ito, S. (2004) Effects of human milk and formula on expression MDR1, MRP2 and CYP3A in the C2BBE1 intestinal cell model Clin Pharmacol Ther, 75, pp. P51.
17. Kwan, P and Sills, GJ and Butler, E and Gant, TW and Brodie, MJ. (2003) Differential expression of multidrug resistance genes in Maive rat brain Neurosci Lett, 339, pp. 33-36.
18. Lin, JH and Yamazaki, M. (2003) Role of P-glycoprotein in pharmacokinetics: Clinical implications Clin Pharmacokinet, 42, pp. 59-98.
19. Luer, MS and Hamani, C and Dujovny, M and Gidal, B and Cwik, M and Deyo, K and Fischer, JH. (1999) Saturable transport of gabepentin at the blood-brain barrier Neurol Res, 21, pp. 559-562.
20. Löscher, W and Potschka, H. (2002) Role of multidrug transporters in pharmacoresistance to antiepileptic drugs J Pharmacol Exp Ther, 301, pp. 7-14.
21. Marchi N, Hallene KL, Kight KM, Cucullo L, Moddel G, Bingaman W, Dini G, Vessani A, Janigro D. 2004. Significance of MDR1 and multiple drug resistance in refractory human epileptic brain, BMC Medicine 2: http://www.biomedcentral.com/1741-7015/2/37
22. Marroni, M and Agrawal, ML and Kight, K and Hallene, KL and Hossain, M and Cucullo, L and Signorelli, K and Namura, S and Bingaman, W and Janigro, D. (2003) Relationship between expression of multiple drug resistance proteins and p53 tumor suppressor gene proteins in human brain astrocytes Neuroscience, 121, pp. 605-617.
23. Marzolini, C and Paus, E and Buclin, T and Kim, RB. (2004) Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance Pers Clin Pharm, 75, pp. 13-33.
24. Morita, Y and Sakaeda, T and Horinouchi, M and Nakamura, T and Kuroda, K and Miki, I and Yoshimura, K and Sakai, T and Shirasaka, D and Tamura, T and Aoyama, N and Kasuga, M and Okumura, K. (2003) MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects Pharm Res, 20, pp. 552-556.
25. Owen, A and Pirmohamed, M and Tettey, JN and Morgan, P and Chadwick, D and Park, BK. (2001) Carbamazepine is not a substrate for P-glycoprotein Br J Clin Pharmacol, 51, pp. 345-349.
26. Pauli-Magnus, C and Feiner, J and Brett, C and Lin, E and Kroetz, DL. (2003) No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects Clin Pharmacol Ther, 74, pp. 487-498.
27. Pendse, S and Briscoe, DM and Frank, M. (2003) P-glycoprotein and alloimmune T-cell activation Clin App Immuno Rev, 4, pp. 3-14.
28. Potschka, H and Loscher, W. (2001a) In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats Epilepsia, 42, pp. 1231-1240.
29. Potschka, H and Loscher, W. (2001b) Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain Neuroreport, 12, pp. 2387-2389.
30. Potschka, H and Fedrowitz, M and Löscher, W. (2002) P-glycoprotein-mediated efflux of phenobarbital, lamotrigine and felbamate at the blood-brain barrier: Evidence from micridialysis experiments in rats Neurosci Lett, 327, pp. 173-176.
31. Raeissi, SD and Hidalgo, IJ and Segura-Aguilar, J and Artursson, P. (1999) Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers Pharm Res, 16, pp. 625-632.
32. Reiss, WG and Oles, KS. (1996) Acetazolamide in the treatment of seizures Ann Pharmacother, 30, pp. 514-519.
33. Rizzi, M and Caccia, S and Guiso, G and Richichi, C and Gorter, JA and Aronica, E and Aliprandi, M and Bagnati, R and Fanelli, R and D'Incalci, M and Samanin, R and Vezzani, A. (2002) Limbic seizures induce P-glycoprotein in rodent brain: Functional implications for pharmacoresistance J Neurosci, 22, pp. 5833-5839.
34. Sadeque, AJM and Wandel, C and He, H and Shah, S and Wood, AJJ. (2000) Increased drug delivery to the brain by P-glycoprotein inhibition Clin Pharmacol Ther, 68, pp. 231-237.
35. Schinkel, AH. (1999) P-glycoprotein, a gatekeeper in the blood-brain barrier Adv Drug Del Rev, 36, pp. 179-194.
36. Schinkel, AH and Wagenaar, E and Mol, CA and van Deemter, L. (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs J Clin Invest, 97, pp. 2517-2524.
37. Schwab, M and Eichelbaum, M and Fromm, MF. (2003) Genetic polymorphisms of the human MDR1 drug transporter Ann Rev Pharmacol Toxicol, 43, pp. 285-307.
38. Siddiqui, A and Kerb, R and Weale, ME and Brinkmann, U and Smith, A and Goldstein, DB and Wood, NW and Sisodiya, SM. (2003) Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1 NEJM, 348, pp. 1442-1448.
39. Sills, GJ and Kwan, P and Butler, E and de Lange, ECM and van den Berg, D and Brodie, MJ. (2002) P-glycoprotein-mediated efflux of antiepileptic drugs: Preliminary studies in mdr1a knockout mice Epilepsy Behav, 3, pp. 427-432.
40. Sills, GJ and Mohanraj, R and Butler, E and McCrindle, S and Collier, L and Wilson, EA and Brodie, MJ. (2005) Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment Epilepsia, 46, pp. 643-647.
41. Sisodiya, SM and Lin, WR and Harding, BN and Squier, MV and Thom, M. (2002) Drug resistance in epilepsy: Expression of drug resistance proteins in common causes of refractory epilepsy Brain, 125, pp. 22-31.
42. Tang, PH and Miles, MV and Glauser, TA and Coletta, L and Doughman, N and Doose, D and Frey, M and DeGrauw, A. (2000) An improved gas-chromatographic assay for topiramate monitoring in paediatric patients Ther Drug Monit, 22, pp. 195-201.
43. Tishler, DM and Weinberg, KI and Hinton, DR and Barbaro, N and Annett, GM and Raffel, C. (1995) MDR1 gene expression in brain of patients with medically intractable epilepsy Epilepsia, 36, pp. 1-6.
44. Tsuji, A and Tamai, I. (1999) Carrier-mediated or specialized transport of drugs across the blood-brain barrier Adv Drug Del Rev, 36, pp. 277-290.
45. Ueda, K and Okamura, N and Hirai, M and Tanigawara, Y and Saeki, T and Kioka, N and Komano, T and Hori, R. (1992) Human P-glycoprotein transports cortisol, aldosterone and dexamethasone, but not progesterone J Biol Chem, 267, pp. 24248-24252.
46. Vandesompele, J and De Preter, K and Pattyn, F and Poppe, B and Van Roy, N and De Paepe, A and Speleman, F. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes Genom Biol, 3(0034), pp. 1-11.
47. Volk, H and Potschka, H and Loscher, W. (2005) Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables J Histochem Cytochem, 53, pp. 517-531.
48. Wacher, V and Salphati, L and Benet, L. (1996) Active secretion and enterocytic drug metabolism barriers to drug absorption Adv Drug Del Rev, 20, pp. 99-112.
49. Weiss, J and Kerpen, CJ and Lindenmaier, H and Dormann, SMG and Haefeli, WE. (2003) Interaction of antiepileptic drugs with human P-glycoprotein in vitro J Pharmacol Exp Ther, 307, pp. 262-267.